Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
Celcuity (CELC) has been drawing attention after a period of strong recent returns, including a gain over the past 3 months, prompting investors to reassess the clinical stage biotech's risk and reward profile. See our latest analysis for Celcuity. At a share price of $107.16, Celcuity's recent 51.85% 3 month share price return sits alongside a very large 1 year total shareholder return, which suggests investors have been rapidly repricing its prospects and risk profile. If Celcuity's move has caught your eye, this can be a good time to scan other US biotechnology names through healthcare stocks for potential ideas in the same space. With Celcuity trading at $107.16 and sitting close to an analyst price target of $110.50, but at a large modelled intrinsic discount, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth? Celcuity's shares trade on a P/B of 42.4x at the last close of $107.16, which is far higher than both
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors [Yahoo! Finance]Yahoo! Finance
- Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances [Yahoo! Finance]Yahoo! Finance
- Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism [Seeking Alpha]Seeking Alpha
- Celcuity Inc.: A Die To Be Cast Before July 2026 [Seeking Alpha]Seeking Alpha
- Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer [Yahoo! Finance]Yahoo! Finance
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 1/29/26 - Form 4
- 1/27/26 - Form 144
- 1/16/26 - Form SCHEDULE
- CELC's page on the SEC website